{"id":"NCT02652624","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women","officialTitle":"A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) From Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-19","primaryCompletion":"2017-10-09","completion":"2018-11-26","firstPosted":"2016-01-12","resultsPosted":"2018-11-02","lastUpdate":"2020-03-04"},"enrollment":472,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"E/C/F/TAF","otherNames":["Genvoya®"]},{"type":"DRUG","name":"E/C/F/TDF","otherNames":["Stribild®"]},{"type":"DRUG","name":"ATV","otherNames":["Reyataz®"]},{"type":"DRUG","name":"RTV","otherNames":["Norvir®"]},{"type":"DRUG","name":"FTC/TDF","otherNames":["Truvada®"]},{"type":"DRUG","name":"B/F/TAF","otherNames":["Biktarvy®"]}],"arms":[{"label":"B/F/TAF","type":"EXPERIMENTAL"},{"label":"Baseline Regimen","type":"ACTIVE_COMPARATOR"},{"label":"Extension Phase","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF), or atazanavir (ATV) + ritonavir (RTV) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically suppressed HIV-1 infected women.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm","timeFrame":"Week 48","effectByArm":[{"arm":"B/F/TAF","deltaMin":1.7,"sd":null},{"arm":"Stay on Baseline Regimen","deltaMin":1.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"1.00"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":56,"countries":["United States","Dominican Republic","Puerto Rico","Russia","Thailand","Uganda"]},"refs":{"pmids":["36912172","31609930"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":234},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Vulvovaginal candidiasis","Urinary tract infection"]}}